NCT06888492View on ClinicalTrials.gov

To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD)

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 28, 2025

Primary Completion Date

April 25, 2026

Study Completion Date

April 30, 2026

Conditions
Wet Age-related Macular Degeneration (wAMD)Wet Age-related Macular Degeneration
Interventions
BIOLOGICAL

EXG202

EXG202 is a gene therapy product for the treatment of wet (neovascular) age-related macular degeneration（wAMD） with a single intravitreal injection and administration.

Trial Locations (2)

322000

The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu

054001

Hebei Eye Hospital, Xingtai

All Listed Sponsors
lead

Hangzhou Jiayin Biotech Ltd

INDUSTRY